Home/INSIGHTS/Norflo/OUR INNOVATIVE IPHYTOONE® FORMULATION WAS RECENTLY TESTED IN JUVENILE IDIOPATHIC ARTHRITIS-ASSOCIATED UVEITIS 

OUR INNOVATIVE IPHYTOONE® FORMULATION WAS RECENTLY TESTED IN JUVENILE IDIOPATHIC ARTHRITIS-ASSOCIATED UVEITIS 

At the 15th annual meeting of the International Ocular Inflammation Society (IOIS), the results of a new study on the utilization of Eye Pharma NORFLO® for the treatment of uveitis associated with juvenile idiopathic arthritis was presented in the form of an e-poster.

The results of this study were very promising with 22 out of 27 patients (81%) reaching uveitis inactivity at the end of the study. Only three episodes of uveitis exacerbations were recorded. Overall, the treatment was well tolerated and no discomforts, ocular side effects or allergic reactions were recorded.

The study was conducted by a team of experts at the San Raffaele hospital in Milan in collaboration with the pediatric rheumatology department of the G.Pini Orthopedic Institute in Milan. NORFLO® was chosen because of the excellent results it had previously shown in clinical settings.

The publication of this important study (Miserocchi E et al, European Journal of Ophthalmology, published online Dec 4, 2019) is a further confirmation of the beneficial action of NORFLO®. Thanks to its further innovated and improved formulation, NORFLO® continues to be an excellent aid in the treatment of chronic inflammatory diseases, significantly improving the patient’s quality of life. Thanks to its new iphytoone® formulation, the addition of phosphatidyl serine increases the product selectivity for nervous tissues, including the retina. This innovative formulation is a further effort by Eye Pharma to improve its products to help counteract and support therapeutic treatment of eye diseases, which are now increasingly widespread.

Several medical centers are introducing NORFLO® as supplement to conventional therapy for diseases linked to chronic eye inflammation, such as uveitis, obtaining excellent results on product tolerability and a decrease in the side effects associated with conventional therapies, often quite invasive.

 

For further information:

E-POSTER STUDY

PUBBLICATION OF THE STUDY

2020-05-08T20:06:10+02:00
Le informazioni, immagini, descrizioni e quanto altro riportato nel sito relativi a dispositivi medici non sono di natura pubblicitaria ma materiale informativo rivolto esclusivamente a Professionisti dell’area sanitaria. Pertanto proseguendo nella navigazione l’utente dichiara di essere un Professionista dell’area sanitaria. Riferimento:Ministero della Salute – “Nuove linee guida della pubblicità sanitaria concernente i dispositivi medici, dispositivi medico-diagnostici in vitro e presidi medico-chirurgici” del 28 Marzo 2013; Aggiornamento delle “Linee guida in merito all’utilizzo di nuovi mezzi di diffusione della pubblicità sanitaria” del 17 Febbraio 2010 - These statements have not been evaluated by the Food & Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Please contact your healthcare professional immediately if you experience any unwanted side effects. The information contained herein is for informational purposes only and does not establish a doctor-patient relationship. Please be sure to consult your physician before taking this or any other product. Statements regarding dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease or health condition.